阿奇霉素治疗小儿支原体肺炎的临床效果(1)
[摘要]目的 研究小兒支原体肺炎应用阿奇霉素治疗的临床疗效。方法 选取2016年2月～2018年2月深圳市宝安区石岩人民医院收治的100例支原体肺炎患儿作为研究对象，根据入院顺序分组将其分为观察组(50例)、对照组(50例)。观察组患儿采用阿奇霉素治疗，对照组患儿采用氨溴索治疗。比较两组患儿的治疗指标、C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、不良反应发生情况、治疗效果。结果 观察组患儿的体温复常时间[(2.01±0.23)d]、咳嗽消失时间[(10.23±1.45)d]、症状好转时间[(6.23±1.22)d]、住院时间[(12.22±1.03)d]均短于对照组[(4.66±1.23)、(12.56±1.82)、(8.78±1.12)、(15.56±1.23)d]，差异有统计学意义(P<0.05)。治疗后，观察组患儿的TNF-α[(11.09±1.66)pg/ml]、IL-6[(12.01±1.24)pg/ml]、CRP[(7.01±1.24)mg/L]均低于对照组[(15.76±1.02)pg/ml、(15.99±1.04)pg/ml、(12.77±1.98)mg/L]，差异有统计学意义(P<0.05)。观察组患儿的不良反应总发生率(2.00%)低于对照组(22.00%)，差异有统计学意义(P<0.05)。观察组患儿的治疗总有效率(96.00%)高于对照组(72.00%)，差异有统计学意义(P<0.05)。结论 小儿支原体肺炎应用阿奇霉素治疗的临床效果十分显著，且安全性高，能够缩短患儿的住院时间，值得研究和推广。
[关键词]小儿支原体肺炎;阿奇霉素;治疗;临床疗效
[中图分类号] R725.6 [文献标识码] A [文章编号] 1674-4721(2020)5(b)-0107-04
Clinical effect of Azithromycin in the treatment of Mycoplasma pneumonia in children
YAN Neng-rong1 WU Zu-cheng2 PENG Xiang-juan3 WANG Si-meng4
1. Department of Pediatrics， the Second People′s Hospital of Bao′an People′s Hospital (Group)， Guangdong Province， Shenzhen 518108， China; 2. Quality Control Center， Shiyan People′s Hospital of Bao′an District in Shenzhen City， Guangdong Province， Shenzhen 518108， China; 3. Department of Neonatology， Shiyan People′s Hospital of Bao′an District in Shenzhen City， Guangdong Province， Shenzhen 518108， China; 4. Department of Brain， Shiyan People′s Hospital of Bao′an District in Shenzhen City， Guangdong Province， Shenzhen 518108， China
[Abstract] Objective To study the clinical effect of Azithromycin on Mycoplasma pneumonia in children. Methods A total of 100 children with mycoplasma pneumoniae from Shiyan People′s Hospital of Baoan District in Shenzhen City from February 2016 to February 2018 were selected as the study subjects. According to their admission order， they were divided into observation group (50 cases) and control group (50 cases). Patients in the observation group were treated with Azithromycin and patients in the control group were treated with Ambroxol. Treatment indicators， C-reactive protein (CRP)， tumor necrosis factor-α (TNF-α)， interleukin-6 (IL-6)， adverse reactions and therapeutic effect were compared between the two groups. Results The temperature recovery time ([2.01±0.23] d)， cough disappearance time ([10.23±1.45] d)， symptom improvement time ([6.23±1.22] d) and hospital stay time ([12.22±1.82] d) of the observation group were all shorter than those of the control group ([4.66±1.23]， [12.56±1.82]， [15.56±1.23] d)， with statistically significant differences (P<0.05). After treatment， TNF-α ([11.09±1.66] pg/ml)， IL-6 ([12.01±1.24] pg/ml) and CRP([7.01±1.24] mg/L) in the observation group were all lower than those in the control group ([15.76±1.02] pg/ml， [15.99±1.04] pg/ml， and [12.77±1.98] mg/L)， with statistically significant differences (P<0.05). The total incidence of adverse reactions in the observation group (2.00%) was lower than that in the control group (22.00%)， and the difference was statistically significant (P<0.05). The total effective rate (96.00%) of the observation group was higher than that of the control group (72.00%)， and the difference was statistically significant (P<0.05). Conclusion Azithromycin is an effective and safe treatment for Mycoplasma pneumonia in children., 百拇医药(鄢能荣 吴祖成 彭向娟 王思梦)
[关键词]小儿支原体肺炎;阿奇霉素;治疗;临床疗效
[中图分类号] R725.6 [文献标识码] A [文章编号] 1674-4721(2020)5(b)-0107-04
Clinical effect of Azithromycin in the treatment of Mycoplasma pneumonia in children
YAN Neng-rong1 WU Zu-cheng2 PENG Xiang-juan3 WANG Si-meng4
1. Department of Pediatrics， the Second People′s Hospital of Bao′an People′s Hospital (Group)， Guangdong Province， Shenzhen 518108， China; 2. Quality Control Center， Shiyan People′s Hospital of Bao′an District in Shenzhen City， Guangdong Province， Shenzhen 518108， China; 3. Department of Neonatology， Shiyan People′s Hospital of Bao′an District in Shenzhen City， Guangdong Province， Shenzhen 518108， China; 4. Department of Brain， Shiyan People′s Hospital of Bao′an District in Shenzhen City， Guangdong Province， Shenzhen 518108， China
[Abstract] Objective To study the clinical effect of Azithromycin on Mycoplasma pneumonia in children. Methods A total of 100 children with mycoplasma pneumoniae from Shiyan People′s Hospital of Baoan District in Shenzhen City from February 2016 to February 2018 were selected as the study subjects. According to their admission order， they were divided into observation group (50 cases) and control group (50 cases). Patients in the observation group were treated with Azithromycin and patients in the control group were treated with Ambroxol. Treatment indicators， C-reactive protein (CRP)， tumor necrosis factor-α (TNF-α)， interleukin-6 (IL-6)， adverse reactions and therapeutic effect were compared between the two groups. Results The temperature recovery time ([2.01±0.23] d)， cough disappearance time ([10.23±1.45] d)， symptom improvement time ([6.23±1.22] d) and hospital stay time ([12.22±1.82] d) of the observation group were all shorter than those of the control group ([4.66±1.23]， [12.56±1.82]， [15.56±1.23] d)， with statistically significant differences (P<0.05). After treatment， TNF-α ([11.09±1.66] pg/ml)， IL-6 ([12.01±1.24] pg/ml) and CRP([7.01±1.24] mg/L) in the observation group were all lower than those in the control group ([15.76±1.02] pg/ml， [15.99±1.04] pg/ml， and [12.77±1.98] mg/L)， with statistically significant differences (P<0.05). The total incidence of adverse reactions in the observation group (2.00%) was lower than that in the control group (22.00%)， and the difference was statistically significant (P<0.05). The total effective rate (96.00%) of the observation group was higher than that of the control group (72.00%)， and the difference was statistically significant (P<0.05). Conclusion Azithromycin is an effective and safe treatment for Mycoplasma pneumonia in children., 百拇医药(鄢能荣 吴祖成 彭向娟 王思梦)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺炎 > 支原体肺炎